Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement
- PMID: 3624207
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement
Abstract
The predictive value of the subjective response after 4 hours to an oral test dose of haloperidol and the predictive value of early clinical improvement during a 28-day, fixed-dose regimen with haloperidol were tested in 33 newly admitted schizophrenic patients. A significant (p less than .01) correlation was found between subjective response and therapeutic outcome on Day 28. Five of the 7 patients with dysphoric responses to the test dose had poor therapeutic outcomes. Powerful relationships were found between therapeutic outcome on Day 28 and clinical improvement observed from Day 2 on and between the outcome at discharge and improvement measured on Days 5 and 6.
Similar articles
-
Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.Pharmacopsychiatry. 1988 Sep;21(5):226-31. doi: 10.1055/s-2007-1014680. Pharmacopsychiatry. 1988. PMID: 3227054 Clinical Trial.
-
[Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].Encephale. 1995 Nov-Dec;21(6):417-24. Encephale. 1995. PMID: 8674466 Clinical Trial. French.
-
Serum prolactin as a correlate of clinical response to haloperidol.J Clin Psychopharmacol. 1991 Dec;11(6):357-61. J Clin Psychopharmacol. 1991. PMID: 1770154 Clinical Trial.
-
Predictors of therapeutic response to haloperidol in acute schizophrenia.Psychopharmacol Bull. 1991;27(2):97-101. Psychopharmacol Bull. 1991. PMID: 1924667 Clinical Trial.
-
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.J Psychiatry Neurosci. 1994 Jul;19(4):254-64. J Psychiatry Neurosci. 1994. PMID: 7918346 Free PMC article. Review.
Cited by
-
Association between depression in chronic phase and future clinical outcome of patients with schizophrenia.Psychopharmacology (Berl). 2022 Mar;239(3):965-975. doi: 10.1007/s00213-022-06099-4. Epub 2022 Feb 21. Psychopharmacology (Berl). 2022. PMID: 35190858
-
Pharmacologic treatment of schizophrenia.Dialogues Clin Neurosci. 2010;12(3):345-57. doi: 10.31887/DCNS.2010.12.3/jkane. Dialogues Clin Neurosci. 2010. PMID: 20954430 Free PMC article. Review.
-
[The initial dysphoric reaction (IDR) to the first dose of neuroleptics].Nervenarzt. 2004 Jan;75(1):36-43. doi: 10.1007/s00115-003-1544-z. Nervenarzt. 2004. PMID: 14722660 German.
-
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.Dialogues Clin Neurosci. 2011;13(2):155-72. doi: 10.31887/DCNS.2011.13.2/ccorrell. Dialogues Clin Neurosci. 2011. PMID: 21842613 Free PMC article. Review.
-
Past and present progress in the pharmacologic treatment of schizophrenia.J Clin Psychiatry. 2010 Sep;71(9):1115-24. doi: 10.4088/JCP.10r06264yel. J Clin Psychiatry. 2010. PMID: 20923620 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical